# Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

> **NCT05824728** · PHASE2 · RECRUITING · sponsor: **Johns Hopkins University** · enrollment: 30 (estimated)

## Conditions studied

- Parkinson Disease Psychosis

## Interventions

- **DRUG:** AGB101

## Key facts

- **NCT ID:** NCT05824728
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-28
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05824728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05824728, "Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05824728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*